1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Distribution of serious and nonserious adverse events days 1–3 or 4 weeks after intrathecal gadobutrol, independent of dose (n = 196)a
iNPH CohortNon-iNPH Cohort
Days 1–34 WeeksDays 1–34 Weeks
Serious adverse events
 Present (No.)0000
 Absent (No.) (%)144 (100%)134 (100%)52 (100%)49 (100%)
Nonserious adverse events
 Present (No.) (%)47 (32.6%)6 (4.5%)30 (57.7%)3 (6.1%)
 Absent (No.) (%)97 (67.4%)128 (95.5%)22 (42.3%)46 (93.9%)
 Missing data (No.)01003
  • a Data are presented as number of individuals (percentage are in parentheses). Comparison of the distribution of nonserious adverse events between the iNPH and non-iNPH cohorts after days 1–3 (Pearson χ2, P = .002) and 4 weeks (Pearson χ2, P = .649).